Background and Purpose-We sought to assess in outpatients with atrial fibrillation and oral anticoagulation (1) whether the complication rate is influenced by the presence of the risk factors age Ͼ65 years, arterial hypertension, diabetes, or previous stroke; (2) whether the complication rate is influenced by the number of additional drugs taken by patients; and (3) 
O ral anticoagulation therapy (OAC) is effective in reducing stroke and embolism by 68% in patients with atrial fibrillation (AF). 1 OAC is particularly recommended if additional risk factors for stroke or embolism, such as age Ͼ65 years, arterial hypertension, diabetes, and previous stroke, are present. 1 Nevertheless, OAC is still underused in elderly patients with AF. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Several patient-, physician-, and healthcare system-related barriers to prescription of OAC have been identified. 16 The underuse of OAC can be explained in part by findings that indicate an increased complication rate in patients on OAC and with increased age, hypertension, diabetes, and previous stroke. [17] [18] [19] [20] [21] [22] [23] [24] [25] It is unknown, however, whether the risk factor by itself or other factors, such as additional drug intake, drug interaction, or other problems, are responsible for the increased complication rate. Therefore, the present study on outpatients with AF and OAC was performed to assess (1) whether the complication rate is influenced by the presence or absence of the risk factors age Ͼ65 years, arterial hypertension, diabetes, and previous stroke; (2) whether the complication rate is influenced by the number of additional drugs and their interactions with OAC; and (3) whether the occurrence of problems and interventions during long-term OAC differs between patients with complications and patients without complications. The present study is a substudy of the Safety in the Therapy With Oral Anticoagulants (STOA) study, an observational trial that seeks to assess problems occurring long-term OAC therapy (C. Stöllberger, MD, unpublished data, 2001 ).
Baseline Investigations
The baseline clinical characteristics and additional medications were registered by a questionnaire that was given to the patient at the start of the study ( Table 1 ). The additional medication was screened for drugs that would potentially interact with OAC. 26 -28 Additionally, each patient received written instructions on the proper use of OAC. Patients who were taking acetylsalicylic acid were advised to stop this medication during OAC. In an effort to minimize the most common bleeding complications, which originated from gastrointestinal and urologic organs, all patients in whom OAC was started during the study period were screened for occult blood losses by guaiac test for occult blood (Hemoccult) and urine probes. 29, 30 In cases with positive occult blood tests or microhematuria, gastroenterologic and urologic investigations were performed. In these patients, OAC was started only if it was deemed safe by the gastroenterologist or urologist.
Appointments
At each appointment the international normalized ratio (INR) value was determined in the hospital laboratory of the KA Rudolfstiftung with the use of the Thrombotest (Nycomed) and a KC 4A test (Amelung). Immediately after the actual INR value was obtained, the patient had a personal appointment with a physician who registered in the patient's "OAC passport" the INR value, prescribed the OAC dosage, set the date of the next appointment, and asked for problems and complications (Tables 2 and 3 ). If needed, interventions and investigations were initiated by the physician. The following parameters were registered for a database: INR value, problems, interventions, occurrence of complications (Tables 2 and 3) , and end points.
If a patient did not attend the scheduled appointment, tracking for him was started, whether the patient was admitted at the investigating hospital or another community hospital in Vienna. If no information could be obtained, the patient was contacted by telephone or mail. If the patient did not respond, the general practitioner or the police were contacted. To document admissions or events that may not have been recalled by the patient, hospital records of all community hospitals in Vienna were screened for the included patients at the end of the study in September 2000.
Complications
Complications were bleeding or thromboembolic events. 31 Bleeding events were classified as minor, serious, life-threatening, and fatal. Minor bleeding required no additional testing, referrals, or outpatient visits but was remarkable enough to be reported to the physician. Serious bleeding included overt gastrointestinal bleeding, occult gastrointestinal bleeding if endoscopic or radiographic studies were done, hematuria that prompted cystoscopy or intravenous urography, and hemoptysis. Bleeding was considered to be life-threatening if it led to cardiopulmonary arrest, surgical or angiographic intervention, intracerebral hemorrhage, or hematothorax or if it resulted in 2 of the following consequences: (1) need for Ն3 units of blood, (2) systolic hypotension (Ͻ90 mm Hg), or (3) anemia with a hematocrit Ͻ20%. Fatal bleeding was defined as that which led directly to the patient's death. Thromboembolic events were classified as minor, serious, life-threatening, and fatal. Minor thromboembolic events, such as superficial thrombophlebitis, required no additional testing, referrals, or outpatient visits but were remarkable enough to be reported to the physician. Serious thromboembolic events included transient ische- mic attacks or prolonged reversible ischemic neurological deficit, minor stroke, recurrent deep venous thrombosis, and pulmonary embolism without respiratory or hemodynamic compromise. Lifethreatening events included massive pulmonary embolism, stroke with residual neurological deficit, or systemic embolism. Fatal thromboembolism was defined as that which led directly to the patient's death. All serious, life-threatening, and fatal complications were independently reviewed by the principal investigator (C.S.) and 1 investigator from another hospital (J.F.). Disagreements were reconciled by discussion.
End Points
Unplanned end points were the discontinuation of OAC because of contraindication or operation, complication, problem, or death not caused by a complication. A planned end point was reached if the patient changed to another institution for control of OAC, if OAC was stopped because it was no longer indicated, or if the patient completed the study period by August 31, 2000.
Statistical Analysis
Simple descriptive statistics were performed for the variables of interest. Continuous variables were compared between groups with 1-way ANOVA, 2-sample Wilcoxon test, or the Kruskal-Wallis test if appropriate. Association between categorical variables was analyzed by contingency tables analysis. Logistic regression was performed to check the influence of age and medication (dichotomized to Յ3 or Ͼ3 drugs) on bleeding complications. All analyses were performed with the statistical software package SAS version 8.1 (SAS Institute). All probability values are 2-tailed. The rates for complications, problems, and interventions were calculated as percentage per 100 patient-years.
Results

Clinical Characteristics and Complications
Included were 360 AF patients with a mean age of 68Ϯ10 years (range, 37 to 88 years). The patients remained in the study for a mean time of 389 days. One hundred twenty-four patients remained in the study Ͻ6 months, and 236 patients remained in the study Ն6 months. Overall, 383 patient-years were observed. The characteristics of the patients and their risk factors for stroke or embolism are listed in Table 1 . Only 47 (13%) of the patients had no risk factor for stroke or embolism. In these patients indication for OAC was mainly attempted electric or pharmacological cardioversion. The drug used for OAC in all patients was phenprocoumon (Marcoumar). The number of additional drugs is listed in Table 1 . The 175 patients taking Յ3 additional drugs were younger than the 185 patients taking Ͼ3 additional drugs (66.5 versus 69.6 years; Pϭ0.0040). One or more drugs known to interact with OAC were taken by 180 patients. The drugs known to interact with OAC that were most commonly taken were amiodarone (nϭ64), allopurinol (nϭ39), simvastatin (nϭ28), levothyroxine (nϭ27), atorvastatin (nϭ25), glimepiride (nϭ20), and metformin (nϭ17). Of the patients who were taking Յ3 additional drugs, 26% took at least 1 interacting drug, whereas of the patients who were taking Ͼ3 additional drugs, 72% took at least 1 interacting drug. During the study period, 3578 appointments took place, at which the INR value was determined. The INR target range was 2.0 to 3.0 for all patients. Sixty-five percent of the INR values were within the target range, 26% were below, and 9% were above. The mean INR value was 2.5Ϯ0.5. Forty-six complications occurred in 37 patients (Tables 2  and 3 ). Thirty-seven were bleeding events, and 9 were thromboembolic events. Of the bleeding events, 17 were assessed as minor, 17 as serious, 2 as life-threatening, and 1 as fatal. Of the thromboembolic events, 1 was assessed as minor, 5 as serious, 2 as life-threatening, and 1 as fatal. The overall complication rate was 14.6%/100 patient-years (Table  2) . Two patients suffered from intracranial bleeding (Table  3) . Unplanned end points occurred in 39 patients: OAC was stopped because of contraindications or operations in 5 patients, because of complications in 6, because of problems in 9, or because of death, not caused by complications, in 19 patients. Planned end points occurred in 321 patients: 78 of them changed to another institution for control of OAC, 60 patients stopped OAC because it was no longer indicated, and 183 patients completed the study.
Complications Related to Duration of OAC
Patients who remained in the study Ͻ6 months did not differ regarding age, sex, clinical characteristics, or risk factors from patients who remained in the study Ն6 months. Patients who remained in the study Ͻ6 months had a higher complication rate than patients who remained in the study Ն6 months (20% versus 12%/100 patient-years; Pϭ0.0234). This higher incidence of complications was mainly due to minor complications, which occurred more often in patients who remained in the study Ͻ6 months than Ն6 months (12% versus 6.8%/100 patient-years; Pϭ0.0314). Thromboembolic complications, however, occurred more rarely in patients who remained in the study Ͻ6 months than Ն6 months (0.0% versus 2.4%/100 patient-years; Pϭ0.0287).
Complications Related to Risk Factors
Patients aged Ͼ65 years (nϭ225) had more serious, lifethreatening, or fatal complications (11% versus 5.3%/100 patient-years; Pϭ0.0428) than patients aged Յ65 years (nϭ135). Patients with hypertension (nϭ208) and without 
Complications Related to Additional Drugs
Patients who took Յ3 drugs had fewer complications than patients who took Ͼ3 drugs (Table 2) . Patients taking drugs known to interact with OAC (nϭ180) did not differ in the complication rate from patients who were taking no interacting drugs (nϭ180).
Patients With and Without Complications
The 37 patients who had complications remained in the study longer than the 323 patients without complications (501 versus 375 days; Pϭ0.0028). The 37 patients with complications ( 
Patients With Bleeding Complications
The incidence of bleeding complications did not differ according to the presence or absence of risk factors for stroke or embolism. The 28 patients who experienced bleeding complications were more often female and took more additional drugs than the 332 patients without bleeding complications (Tables 1 and 3) . Although the mean age of the patients who experienced bleeding complications was higher than that of patients without, this difference was not significant. Furthermore, the clinical characteristics and the prevalence of risk factors for stroke and embolism did not differ between patients with bleeding complications and patients without. Logistic regression showed a significant influence of the number of additional drugs on bleeding complications (PϽ0.02). Above all, there was a significant difference in the variable age between the medication groups.
Discussion
This study in AF patients on OAC shows that the complication rate is higher in patients aged Ͼ65 years than in younger patients, higher in patients with diabetes than in patients without diabetes, and higher in patients who take Ͼ3 additional drugs per day than in patients who take Յ3 drugs per day. These differences in the complication rate, however, cannot be explained by the intake of drugs known to interact with OAC. The complication rate is not influenced by the presence or absence of arterial hypertension or previous stroke. Patients with advanced age have been shown to be more prone to complications of OAC than younger patients. 17, [19] [20] [21] [22] [23] [24] [25] 32 Only a few studies have shown that advanced age by itself does not increase the complication rate of OAC. 31, [33] [34] [35] Differences in clinical characteristics, indications for OAC, and prevalence of comorbid conditions may explain these differences. It is possible that elderly patients are less able to compensate for blood losses than younger patients, thus leading to a higher rate of life-threatening and fatal complications. This hypothesis is substantiated by an additional study and our findings. 36 An additional factor in the higher complication rate of OAC in elderly patients may be increased comorbidity, leading to more potential bleeding sources and coagulopathies.
Arterial hypertension has been identified as a risk factor for complications of OAC by several studies, 17, 21, 37 whereas other studies could not find an association. 31, 33 Although in our study arterial hypertension was the most prevalent coexisting disease, being prevalent in 58% of the patients, it did not influence the complication rate. It is possible that increased awareness of the patients and their general practitioners of blood pressure control under OAC therapy and participation in the present study may have played a role.
Only a few studies have investigated the role of diabetes mellitus as a risk factor for complications of OAC. 22, 25, 37 A recent study in AF patients found a higher frequency of major primary bleeding complications in diabetic patients. 25 One study in patients who mainly had heart valve prostheses found diabetes to increase the risk of bleeding complications 22 ; another study in patients after reconstruction for limb ischemia found insulin-dependent diabetes mellitus to increase the risk for hemorrhagic stroke. 37 Similarly, in our study the rate of life-threatening and fatal, but not minor, bleeding complications was higher in patients with than without diabetes. This finding might be explained by the high polymorbidity of diabetic patients, most probably due to diabetic vasculopathy.
Previous stroke has been identified as a risk factor for bleeding complications by 1 post hoc analysis of AF patients and in 1 prospective study of primarily patients with heart valve prostheses. 17, 22 Other studies, however, could not find this relationship. 31, 33 The largest prospective study in patients with AF and stroke, however, did not show an increased rate of bleeding and showed only a slightly increased rate of thromboembolic complications compared with other studies on OAC in AF (Table 4) . 38 Additionally, in our study previous stroke was not a risk factor for complications. Again, patients' characteristics and differences in the INR target range may explain the discrepant findings concerning the role of previous stroke as a risk factor for complications of OAC.
Only a few studies have evaluated the influence of additional drug intake on the complication rate of OAC. The use of multiple medications was identified as a risk factor for bleeding complications by 3 studies. 17, 21, 35 In 2 other studies it did not have an influence on the complication rate. 31, 34 Again, these discrepancies might be explained by the different patients' characteristics. In our study only 13% of the patients were without additional medication, and the mean number of drugs was 3.6 drugs per day. A high number of additional drugs reflects the degree of a patient's morbidity. 39, 40 This was also supported by the present study. Accordingly, the complication rate of OAC was increased in patients taking Ͼ3 additional drugs per day compared with patients taking Յ3 additional drugs per day. Since the complication rate did not differ between patients taking drugs known to interact with OAC and those who did not take interacting drugs, it may be inferred that the increased complication rate of patients with multiple medications is a consequence of comorbidity rather than of drug interaction.
Patients who experienced complications complained more often about chest or abdominal pain than patients who experienced no complications. This again may be a consequence of comorbidity. Another explanation may be uncontrolled and unreported intake of nonsteroidal anti-inflammatory drugs, thus leading to bleeding complications due to drug interaction or mucosal damage. Some of the patients who complained of chest pain probably suffered from coronary heart disease. Acetylsalicylic acid, however, was never recommended to them as long as they were on OAC. Patients with complications were less compliant than patients without complications. One reason might be increased morbidity leading to bed rest and hospitalization, making patients unable to attend the scheduled appointments. Another reason might be lack of awareness about the importance of OAC monitoring. This again stresses the need for consequent education and careful monitoring of patients with OAC.
In our study the duration of follow-up was relatively short compared with other studies (Table 4) . Because most of the complications tend to occur in the first months after OAC is initiated, 20, 24, 31, 33 it is possible that some of the incidence rates for complications may be overestimated. This possibility is substantiated by the finding that complications, mainly minor, were more frequent in patients who remained in the study Ͻ6 months than in patients who remained Ն6 months.
The complication rate is a measure of the quality and efficacy of OAC. Compared with previous observational trials reporting a major bleeding rate of 5% to 7%/100 patient-years, 22, 24, 36 the complication rate in the present study was lower but similar to those of controlled clinical trials (Table 4) . 38, [41] [42] [43] [44] [45] [46] One reason for the low complication rate in these controlled clinical trials might be the exclusion of patients potentially at risk for bleeding or thromboembolic complications. Additionally, the surveillance of patients in the later 4 studies was excellent because the design of the studies was that of a randomized controlled trial. Potential explanations for the low complication rates in the present study are as follows: (1) Potential bleeding sites in the gastrointestinal and urologic tracts were localized and eliminated before initiation of OAC, a procedure that was not integrated in other studies. (2) All patients in our study had an INR target range of 2.0 to 3.0. It is known that the intensity of anticoagulation is an important risk factor for bleeding and thromboembolic complications during OAC. 31,34 -36 (3) In the present investigation a physician talked personally to the patient at each appointment and decided promptly whether and which interventions should be performed. The importance of a direct relationship with the physician during OAC monitoring has been emphasized recently. 47 From our findings we conclude that patients with increased age or diabetes mellitus or those who take Ͼ3 drugs per day have a higher complication rate and thus need especially careful monitoring of OAC. To minimize the number of complications, special care must be taken to ensure adequate pain control and compliance of the patients. 
